Holen Sie sich die Stockscreener-App
133.89
0.46%
-0.62
Handel nachbörslich:
133.89
Schlusskurs vom Vortag:
$134.51
Offen:
$134.5
24-Stunden-Volumen:
582.33K
Relative Volume:
0.55
Marktkapitalisierung:
$13.35B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
45.39
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
-0.48%
1M Leistung:
-7.83%
6M Leistung:
+1.32%
1J Leistung:
-9.65%
1-Tages-Spanne:
$133.54
$136.51
1-Wochen-Bereich:
$133.54
$138.74
52-Wochen-Spanne:
$84.23
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
133.89 | 13.41B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
124.96 | 54.61B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.91 | 52.47B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.42 | 46.18B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.53 | 36.87B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
476.78 | 20.38B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Eingeleitet | Citigroup | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Does Neurocrine Biosciences (NBIX) Price Weakness Signal A Long Term Opportunity? - simplywall.st
Assessing Neurocrine Biosciences (NBIX) Valuation After New Phase 2 VMAT2 Tardive Dyskinesia Trial Launch - Yahoo Finance
Higher VMAT2 Target Occupancy Observed in Valbenazine Over Deutetrabenazine Extended-Release Capsules - Neurology Live
Neurocrine Biosciences begins Phase II NBI-1065890 trial for TD - Clinical Trials Arena
Neurocrine initiates phase 2 study for tardive dyskinesia treatment By Investing.com - Investing.com India
Gainers Report: What is Neurocrine Biosciences Inc.’s TAM (Total Addressable Market)2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Neurocrine Biosciences, Inc. Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia - marketscreener.com
Neurocrine initiates phase 2 study for tardive dyskinesia treatment - Investing.com
Neurocrine Biosciences, Inc. $NBIX Holdings Lifted by Wealth Enhancement Advisory Services LLC - MarketBeat
Neurocrine tests potential longer-acting tardive dyskinesia treatment - Stock Titan
New INGREZZA VMAT2 Data vs AUSTEDO XR Might Change The Case For Investing In Neurocrine (NBIX) - simplywall.st
Volume Report: How cyclical is Neurocrine Biosciences Incs revenue stream2025 Volume Leaders & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
(NBIX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Assessing Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Clinical Data And Pipeline Updates - simplywall.st
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $178.00 at UBS Group - MarketBeat
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $178 - 富途牛牛
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock - Chartmill
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive? - primepublishers.com
Recap Report: Why is Neurocrine Biosciences Inc stock going up2025 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results - The AI Journal
Neurocrine sets Feb. 11 webcast for Q4 and 2025 year-end financial results - Stock Titan
Aug Analyst Calls: Is Momentus Inc Equity Warrant a momentum stockQuarterly Trade Summary & Expert Curated Trade Setups - baoquankhu1.vn
Rakuten Investment Management Inc. Makes New Investment in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) CEO Kyle Gano Sells 36,400 Shares - MarketBeat
Seizert Capital Partners LLC Invests $9.83 Million in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Aug Wrap: What hedge funds are buying Neurocrine Biosciences IncJuly 2025 Intraday Action & Verified Stock Trade Ideas - baoquankhu1.vn
Stock Market Recap: Is Neurocrine Biosciences Inc a turnaround storyQuarterly Performance Summary & Weekly Stock Performance Updates - baoquankhu1.vn
Neurocrine Biosciences officer sells $168,849 in stock - MSN
Neurocrine Biosciences chief commercial officer sells $115,940 in stock - MSN
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 21,900 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Position Reduced by Sumitomo Mitsui Trust Group Inc. - MarketBeat
Campbell & CO Investment Adviser LLC Acquires Shares of 16,470 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
How Investors Are Reacting To Neurocrine Biosciences (NBIX) INGREZZA’s VMAT2 Edge Over AUSTEDO XR - simplywall.st
Neurocrine Biosciences executive sells shares worth $82,792 - MSN
A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Head To Head Clinical Data - simplywall.st
Neurocrine presents data showing INGREZZA achieved higher target occupancy - StreetInsider
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR - wvnews.com
Neurocrine Biosciences describes new GLP-1R/GIPR/GCGR agonists - BioWorld MedTech
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by SG Americas Securities LLC - MarketBeat
Brain scan study finds INGREZZA hits key movement target twice as hard - Stock Titan
With Neurocrine Biosciences, Inc. (NASDAQ:NBIX) It Looks Like You'll Get What You Pay For - 富途资讯
Major Decision: Darin Lippoldt Exercises Options, Realizing $320K At Neurocrine Biosciences - Benzinga
Neurocrine Biosciences, Inc. $NBIX Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Gap Down: Can Neurocrine Biosciences Inc be recession proofBreakout Watch & Verified Momentum Watchlists - baoquankhu1.vn
Price-Driven Insight from (NBIX) for Rule-Based Strategy - Stock Traders Daily
Investor Mood: What is the Moat Score of Harbor Etf Trust Smid Capital Value EtfWeekly Trading Summary & Reliable Entry Point Alerts - baoquankhu1.vn
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Lobbying Update: $60,000 of NEUROCRINE BIOSCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Neurocrine Biosciences CEO sells $235,577 in stock - MSN
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
9.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):